<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567824</url>
  </required_header>
  <id_info>
    <org_study_id>MLD 10-003</org_study_id>
    <nct_id>NCT03567824</nct_id>
  </id_info>
  <brief_title>MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2 Open Label Study of Magnesium L-Lactate Dihydrate (MLD10) 10 mEq Extended-Release Caplets Administered BID for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus Followed by a Blinded Random Off Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmalyte Solutions LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmalyte Solutions LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of MLD10 (magnesium L-lactate dihydrate extended-release caplets) 10
      mEq BID on serum magnesium in Type 2 diabetic patients with hypomagnesemia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will be treated open label for the first 3 months on study, then randomized to receive either active or placebo for an additional 3 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The second phase of the study where subjects are randomized to either active or placebo will be blinded to both participant and investigator.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Magnesium Concentration</measure>
    <time_frame>Three months after the initiation of treatment and then at 3 months after the start of the random off phase.</time_frame>
    <description>Change from baseline in serum magnesium concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Magnesium Concentration.</measure>
    <time_frame>At 1 and 2 months after the initiation of treatment.</time_frame>
    <description>Change from baseline in serum magnesium concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Glucose</measure>
    <time_frame>Three months after the initiation of treatment and then at 3 months after the start of the random off phase.</time_frame>
    <description>Change from baseline in fasting blood glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Sensitivity</measure>
    <time_frame>Three months after the initiation of treatment and then at 3 months after the start of the random off phase.</time_frame>
    <description>Change from baseline in insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance</measure>
    <time_frame>Three months after the initiation of treatment and then at 3 months after the start of the random off phase.</time_frame>
    <description>Change from baseline in insulin resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Three months after the initiation of treatment and then at 3 months after the start of the random off phase.</time_frame>
    <description>Change from baseline in HbA1c.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypomagnesemia in Type 2 Diabetic Patients</condition>
  <arm_group>
    <arm_group_label>Open label phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Random off phase</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium L-lactate dihydrate</intervention_name>
    <description>Magnesium L-lactate dihydrate 10 mEq extended release caplets</description>
    <arm_group_label>Open label phase</arm_group_label>
    <arm_group_label>Random off phase</arm_group_label>
    <other_name>MLD10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo will have the same appearance, taste, odor and mode of administration as MLD10.</description>
    <arm_group_label>Random off phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females and males with Type 2 diabetes mellitus

          -  Body Mass Index between 18 to 40 kg/m2, inclusive, at Screening

          -  Hypomagnesemia defined as serum magnesium â‰¤ 1.5 mg/dL at Screening

          -  Females must be non-pregnant, non-lactating, and have a negative serum pregnancy test
             before enrollment.

        Exclusion Criteria:

          -  History of clinically significant GI, renal, hepatic, neurologic, hematologic,
             endocrine other than Type 2 diabetes mellitus, oncologic, pulmonary, immunologic,
             psychiatric, or cardiovascular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Steve F Brandon</last_name>
    <phone>817.421.2777</phone>
    <email>sbrandon@niche-inc.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

